Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment

Naoki Niikura, Morihiko Kimura, Takayuki Iwamoto, Naoki Hayashi, Junichi Shintoku, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We attempted to determine the preferences of women regarding the benefits they considered necessary to make adjuvant therapy worthwhile, and to compare preferences for adjuvant endocrine therapy, chemotherapy, and trastuzumab therapy. We also investigated the effect of information about cost on women's treatment preferences. Patients and methods: Consecutive women who had a medical examination at the Breast Clinic, Ota General Hospital, were included in our study. We collected a questionnaire from a total of 365 women; 297 completed responses were included in the study. Results: Among 297 women, 105 had breast cancer that had been treated and 192 did not have breast cancer; 38% of women judged that a 5% or less gain in the probability of survival was sufficient to make endocrine therapy worthwhile; 28% of participants judged that chemotherapy was worthwhile; 24% of participants judged that trastuzumab therapy was worthwhile. Women indicated that they were more likely to receive adjuvant endocrine therapy than chemotherapy or trastuzumab therapy, for the same gains in the probability of survival. Cost information about treatments did not affect women's treatment preferences. Younger women tended to judge improvements in survival sufficient to make adjuvant endocrine and chemotherapy worthwhile, as compared to older women. The comparisons were statistically significant in the 10 and 20% categories for endocrine therapy and chemotherapy. Conclusion: Women prefer endocrine therapy to chemotherapy or trastuzumab therapy, given the same projected treatment benefits. Younger women prefer both chemotherapy and endocrine therapy as compared with older woman.

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalBreast Cancer
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Survival
Costs and Cost Analysis
Adjuvant Chemotherapy
General Hospitals
Breast
Trastuzumab

Keywords

  • Adjuvant therapy
  • Breast cancer
  • Preference

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Niikura, N., Kimura, M., Iwamoto, T., Hayashi, N., Shintoku, J., Saito, Y., ... Tokuda, Y. (2013). Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. Breast Cancer, 20(1), 67-74. https://doi.org/10.1007/s12282-011-0310-5

Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. / Niikura, Naoki; Kimura, Morihiko; Iwamoto, Takayuki; Hayashi, Naoki; Shintoku, Junichi; Saito, Yuki; Suzuki, Yasuhiro; Tokuda, Yutaka.

In: Breast Cancer, Vol. 20, No. 1, 01.2013, p. 67-74.

Research output: Contribution to journalArticle

Niikura, N, Kimura, M, Iwamoto, T, Hayashi, N, Shintoku, J, Saito, Y, Suzuki, Y & Tokuda, Y 2013, 'Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment', Breast Cancer, vol. 20, no. 1, pp. 67-74. https://doi.org/10.1007/s12282-011-0310-5
Niikura, Naoki ; Kimura, Morihiko ; Iwamoto, Takayuki ; Hayashi, Naoki ; Shintoku, Junichi ; Saito, Yuki ; Suzuki, Yasuhiro ; Tokuda, Yutaka. / Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. In: Breast Cancer. 2013 ; Vol. 20, No. 1. pp. 67-74.
@article{b02bfd4ea1b146eab9e07b6a73fbb989,
title = "Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment",
abstract = "Background: We attempted to determine the preferences of women regarding the benefits they considered necessary to make adjuvant therapy worthwhile, and to compare preferences for adjuvant endocrine therapy, chemotherapy, and trastuzumab therapy. We also investigated the effect of information about cost on women's treatment preferences. Patients and methods: Consecutive women who had a medical examination at the Breast Clinic, Ota General Hospital, were included in our study. We collected a questionnaire from a total of 365 women; 297 completed responses were included in the study. Results: Among 297 women, 105 had breast cancer that had been treated and 192 did not have breast cancer; 38{\%} of women judged that a 5{\%} or less gain in the probability of survival was sufficient to make endocrine therapy worthwhile; 28{\%} of participants judged that chemotherapy was worthwhile; 24{\%} of participants judged that trastuzumab therapy was worthwhile. Women indicated that they were more likely to receive adjuvant endocrine therapy than chemotherapy or trastuzumab therapy, for the same gains in the probability of survival. Cost information about treatments did not affect women's treatment preferences. Younger women tended to judge improvements in survival sufficient to make adjuvant endocrine and chemotherapy worthwhile, as compared to older women. The comparisons were statistically significant in the 10 and 20{\%} categories for endocrine therapy and chemotherapy. Conclusion: Women prefer endocrine therapy to chemotherapy or trastuzumab therapy, given the same projected treatment benefits. Younger women prefer both chemotherapy and endocrine therapy as compared with older woman.",
keywords = "Adjuvant therapy, Breast cancer, Preference",
author = "Naoki Niikura and Morihiko Kimura and Takayuki Iwamoto and Naoki Hayashi and Junichi Shintoku and Yuki Saito and Yasuhiro Suzuki and Yutaka Tokuda",
year = "2013",
month = "1",
doi = "10.1007/s12282-011-0310-5",
language = "English",
volume = "20",
pages = "67--74",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment

AU - Niikura, Naoki

AU - Kimura, Morihiko

AU - Iwamoto, Takayuki

AU - Hayashi, Naoki

AU - Shintoku, Junichi

AU - Saito, Yuki

AU - Suzuki, Yasuhiro

AU - Tokuda, Yutaka

PY - 2013/1

Y1 - 2013/1

N2 - Background: We attempted to determine the preferences of women regarding the benefits they considered necessary to make adjuvant therapy worthwhile, and to compare preferences for adjuvant endocrine therapy, chemotherapy, and trastuzumab therapy. We also investigated the effect of information about cost on women's treatment preferences. Patients and methods: Consecutive women who had a medical examination at the Breast Clinic, Ota General Hospital, were included in our study. We collected a questionnaire from a total of 365 women; 297 completed responses were included in the study. Results: Among 297 women, 105 had breast cancer that had been treated and 192 did not have breast cancer; 38% of women judged that a 5% or less gain in the probability of survival was sufficient to make endocrine therapy worthwhile; 28% of participants judged that chemotherapy was worthwhile; 24% of participants judged that trastuzumab therapy was worthwhile. Women indicated that they were more likely to receive adjuvant endocrine therapy than chemotherapy or trastuzumab therapy, for the same gains in the probability of survival. Cost information about treatments did not affect women's treatment preferences. Younger women tended to judge improvements in survival sufficient to make adjuvant endocrine and chemotherapy worthwhile, as compared to older women. The comparisons were statistically significant in the 10 and 20% categories for endocrine therapy and chemotherapy. Conclusion: Women prefer endocrine therapy to chemotherapy or trastuzumab therapy, given the same projected treatment benefits. Younger women prefer both chemotherapy and endocrine therapy as compared with older woman.

AB - Background: We attempted to determine the preferences of women regarding the benefits they considered necessary to make adjuvant therapy worthwhile, and to compare preferences for adjuvant endocrine therapy, chemotherapy, and trastuzumab therapy. We also investigated the effect of information about cost on women's treatment preferences. Patients and methods: Consecutive women who had a medical examination at the Breast Clinic, Ota General Hospital, were included in our study. We collected a questionnaire from a total of 365 women; 297 completed responses were included in the study. Results: Among 297 women, 105 had breast cancer that had been treated and 192 did not have breast cancer; 38% of women judged that a 5% or less gain in the probability of survival was sufficient to make endocrine therapy worthwhile; 28% of participants judged that chemotherapy was worthwhile; 24% of participants judged that trastuzumab therapy was worthwhile. Women indicated that they were more likely to receive adjuvant endocrine therapy than chemotherapy or trastuzumab therapy, for the same gains in the probability of survival. Cost information about treatments did not affect women's treatment preferences. Younger women tended to judge improvements in survival sufficient to make adjuvant endocrine and chemotherapy worthwhile, as compared to older women. The comparisons were statistically significant in the 10 and 20% categories for endocrine therapy and chemotherapy. Conclusion: Women prefer endocrine therapy to chemotherapy or trastuzumab therapy, given the same projected treatment benefits. Younger women prefer both chemotherapy and endocrine therapy as compared with older woman.

KW - Adjuvant therapy

KW - Breast cancer

KW - Preference

UR - http://www.scopus.com/inward/record.url?scp=84872606031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872606031&partnerID=8YFLogxK

U2 - 10.1007/s12282-011-0310-5

DO - 10.1007/s12282-011-0310-5

M3 - Article

C2 - 22109640

AN - SCOPUS:84872606031

VL - 20

SP - 67

EP - 74

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

ER -